NRX Pharmaceuticals Inc — Cash Flow (NASDAQ:NRXP) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities -37.7 M-39.76 M-21.66 M-10.64 M-14.11 M -14.11 M Cash from investing activities -7 000-10 K-3 0000-2.81 M — Cash from financing activities 63.46 M32.21 M6.2 M7.49 M23.28 M 23.28 M Free cash flow -37.71 M-39.77 M-21.66 M-10.64 M-14.11 M -14.11 M

Haberler

NRx Pharmaceuticals, Glenn Tyson’ı ticari direktör olarak atadı

NRx, ketamin etiketlemesinde FDA ile ön uyum sağladı

Hope Therapeutics, yapay zeka izleme aracı için Emobot ile ortaklık kurdu

BTIG, FDA ilerlemesi sonrası NRx Pharmaceuticals hissesi için Al önerisini korudu

NRX Pharmaceuticals 2025 4Ç’de operasyonel ilerlemeler kaydetti

NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates

NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript

NRx Pharmaceuticals FDA’dan biyoeşdeğerlik onayı aldı

NRx Pharmaceuticals receives FDA bioequivalence approval notice

NRx Pharmaceuticals receives FDA guidance on NRX-100 drug application

VTSAX vs. VTI: Which Vanguard Fund Should You Buy in 2026? - TipRanks.com

H.C. Wainwright, NRx Pharmaceuticals hisse hedefini 45 dolara yükseltti